This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Castro-Gago, M. Articles by Devesa, J. Search for Related Content PubMed PubMed Citation Articles by Castro-Gago, M. Articles by Devesa, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Muscle Disorders Social Bookmarking                         What's this?

Muscle Myostatin Expression in Children With Muscle Diseases

Departamento de Pediatría, Servicio de Neuropediatría, Hospital Clínico Universitario, Santiago de Compostela, Spain, pdcastro@ usc.es

Carmen Gómez-Lado, MD

Departamento de Pediatría, Servicio de Neuropediatría, Hospital Clínico Universitario, Santiago de Compostela, Spain

Jesús Eiris-Puñal, MD

Departamento de Pediatría, Servicio de Neuropediatría, Hospital Clínico Universitario, Santiago de Compostela, Spain

Isabel Carneiro, MD

Departamento de Fisiología, Facultad de Medicina, Universidad de Santiago de Compostela, Spain

Víctor Manuel Arce, MD

Departamento de Fisiología, Facultad de Medicina, Universidad de Santiago de Compostela, Spain

Jesús Devesa, MD

Departamento de Fisiología, Facultad de Medicina, Universidad de Santiago de Compostela, Spain

The demonstration that myostatin may negatively regulate muscle mass in adult individuals has raised the possibility of targeting the myostatin pathway to increase muscle growth in a variety of muscle-degenerative and -wasting conditions. To gain further insight into the possible role of myostatin in primary muscle diseases, the authors investigated the expression of muscle myostatin in children with congenital fiber type 1 disproportion, in others with neurogenic muscular atrophy, in others with myotonia congenita, in others with infantile glycogenosis type II, in others with Prader-Willi syndrome, and in 4 age-matched controls. No differences in the pattern of myostatin expression were found in any case, even in those patients with prominent muscular atrophy or hypertrophy. These findings suggest that muscle alterations that can be observed in primary muscle diseases do not depend on changes in myostatin expression.

Key Words: congenital fiber type disproportion • glycogenosis type II • myostatin • myotonia congenital • neurogenic muscular atrophy • Prader-Willi syndrome

Journal of Child Neurology, Vol. 22, No. 1, 38-40 (2007)
DOI: 10.1177/0883073807299966


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?